Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Alnylam Pharmaceuticals (NQ: ALNY )

188.66 +3.65 (+1.97%)
Streaming Delayed Price Updated: 11:40 AM EDT, Jun 1, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 72,640
Open 185.81
Bid (Size) 188.75 (1)
Ask (Size) 188.97 (2)
Prev. Close 185.01
Today's Range 184.07 - 189.61
52wk Range 120.43 - 242.97
Shares Outstanding 118,847,693
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
What 10 Analyst Ratings Have To Say About Alnylam Pharmaceuticals
 
Via Benzinga
Analyst Says Alnylam's New Patisiran Data Shows Disease Slowing With Early Intervention, But Survival Benefit Remains Of Interest
Alnylam Pharmaceuticals Inc (NASDAQ: ALNY) released new results from an interim analysis of exploratory data from the open-label extension (OLE) period of the APOLLO-B Phase 3 study of patisiran, for... 
Via Benzinga

Performance

YTD
-19.23%
-19.23%
1 Month
-6.54%
-6.54%
3 Month
-3.45%
-3.45%
6 Month
-14.53%
-14.53%
1 Year
+49.97%
+49.97%

More News

Read More
Alnylam Presents 18-Month Results from the APOLLO-B Phase 3 Study of Patisiran in Patients with ATTR Amyloidosis with Cardiomyopathy
From Alnylam
Via Business Wire
Looking Into Alnylam Pharmaceuticals's Recent Short Interest
Via Benzinga
$1000 Invested In This Stock 15 Years Ago Would Be Worth $7,600 Today
Via Benzinga
Where Alnylam Pharmaceuticals Stands With Analysts
Via Benzinga
Alnylam Clocks ~50% Revenue Growth In Q1 On Solid Commercial Execution
Via Benzinga
How To Attend Alnylam Pharmaceuticals Q1 2023 Earnings Conference Call
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For May 5, 2023
Via Benzinga
Alnylam Pharmaceuticals Reports First Quarter 2023 Financial Results and Highlights Recent Period Activity
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
$1000 Invested In This Stock 5 Years Ago Would Be Worth $2,100 Today
Via Benzinga
A Bearish Sign Appears On Alnylam Pharmaceuticals's Chart
Via Benzinga
Here's How Much $100 Invested In Alnylam Pharmaceuticals 5 Years Ago Would Be Worth Today
Via Benzinga
Alnylam to Webcast Presentation at BofA Securities 2023 Health Care Conference
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
Alnylam Issues 2022 Corporate Responsibility Report
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
Alnylam - Regeneron Partnered Alzheimer's Candidate's Initial Data Sounds Promising, Analyst Says
Via Benzinga
Alnylam and Regeneron Report Positive Interim Phase 1 Clinical Data on ALN-APP, an Investigational RNAi Therapeutic for Alzheimer’s Disease and Cerebral Amyloid Angiopathy
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
Regeneron and Alnylam Report Positive Interim Phase 1 Clinical Data on ALN-APP, an Investigational RNAi Therapeutic for Alzheimer’s Disease and Cerebral Amyloid Angiopathy
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Why Legend Biotech Stock Is Having Its Best Month Yet
Via MarketBeat
3 Pharma Stocks That Could See a Surge in Demand in 2023
Via InvestorPlace
Alnylam to Webcast Conference Call Discussing First Quarter 2023 Financial Results
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Analyst Upgrades Arrowhead Pharma Citing 'Attractive Risk/Reward'
Via Benzinga
Pfizer Slapped With Additional Patent Infringement Lawsuit Over Its Famed COVID-19 Shots
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For March 21, 2023
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.